Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published ...
Sep 1, 2011
0
0